Kornimate/medical-research-clean huggingface dataset:
acute response to cigarette and e-cigarette smoking assesed in exhaled breath condensate in healthy smokers of traditional and e-cigarettes

Conditions: E-cigarettes

Summary: electronical cigarettes, also known as "e-cigarettes" are a new phenomenon, which steadily wins more aprobation among smokers. however, there exists no much data concerning the effects of acute exposure to electronic cigarettes vapour on the respiratory system. the aim of the present study is to evaluate and compare the acute response to electronic and traditional cigarettes in healthy smokers.

the aim of the study is: * to evaluate the acute response to traditional cigarettes on the respiratory system * to evaluate the acute response to electronic cigarettes on the respiratory system * to assess the relationship between the type of smoked cigarettes (traditional vs. electronic) and concentration of markers of airway inflammation released in healthy smokers material and methods: * 29 healthy smokers of traditional cigarettes * 29 healthy smokers of electronic cigarettes * 29 healthy, nonsmoking volunteers after 8 hours of smoking abstinence: * the spirometry test * the first collection of the exhaled breath condensate (ebc i) * smoking a traditional / electronic cigarette * the second collection of the exhaled breath condensate (ebc ii) - one hour after smoking * the third collection of the exhaled breath condensate (ebc iii) - six hours after smoking * the measurement of biomarkers of oxidative stress in the ebc (isoprostane-8, malondialdehyde mda, il-8) and ph of the ebc

Eligibility criteria:
inclusion criteria: * healthy smokers of traditional cigarettes - min. 1 packyear * healthy smokers of e-cigarettes - min. 1 year of smoking history * control group - healthy nonsmoking volunteers without any history of lung disease exclusion criteria: * age below 18 years * inhaled corticosteroid therapy at least 6 weeks prior to study enrollment * any co-morbidities * respiratory infections at least 6 weeks prior to study enrollment

Keywords: e-cigarettes
cemented trendhip® - multicenter pmcf study on total indications

Conditions: Coxarthrosis; Primary; Coxarthrosis; Post-Traumatic; Necrosis, Femur Head; Rheumatoid Arthritis; Fractures, Hip; Hip Dysplasia

Summary: this post market clinical follow-up (pmcf) study to evaluate the performance and safety of the cemented trendhip® stem in a prospective follow-up study with patients who underwent a hip arthroplasty with the investigational product (representative of usual clinical practice), at two follow-up examinations


Eligibility criteria:
inclusion: inclusion criteria * patient older than 18 years. * patient who undergo / underwent a hip arthroplasty with cemented trendhip® femoral stem according to the indications for implantation specified in the instructions for use. * patient not opposing participation in the study. exclusion: exclusion criteria * patient with shortened life expectancy. * the patient is unable to commit to the planned follow-up period.

Keywords: total hip arthroplasty hip prosthesis elderly patients bone cement
to establish a molecular typing system for early diagnosis of lung cancer

Conditions: Lung Cancer

Summary: this topic to take large multicenter study real world, the advanced liquid biopsy will ctdna methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of early lung cancer screening and diagnosis of molecular classification system model, the feasibility of the development of early lung cancer screening and diagnosis of molecular classification system, improve its early screening early detection accuracy and efficiency, improve the survival status of lung cancer high-risk population. at the same time, this project combined ai analysis technology of ldct image results with ctdna methylation detection, so as to overcome false negatives caused by the deficiency of ctdna methylation detection technology in sensitivity, specificity, stability and flux, and correct false positive results that may be caused by ai analysis technology of ldct image results. the combination of the two can avoid missed diagnosis and over - examination and over - treatment.

1. all patients underwent low-dose ct pulmonary nodule ai detection and peripheral blood ctdna methylation detection at baseline 2. follow-up plan: low-risk and medium-risk nodules and some high-risk nodules (5-10mm) were followed up. 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study. the high-risk nodules over 10mm were evaluated by the expert group and the patients were informed by biopsy or surgical resection. histopathological diagnosis was made and compared with ctdna methylation results to analyze the sensitivity and specificity of ctdna methylation markers of lung cancer. 3. endpoint: tissue samples were pathologically diagnosed as benign or malignant.

Eligibility criteria:
inclusion criteria: 1. patients with pulmonary nodules confirmed by chest ct are not limited to single nodules; 2. nodule diameter 5-30mm 3. nodules include solid, semi-solid and ground glass nodules; 4. age 18-75, no gender limitation; 5. the newly diagnosed patients did not receive surgery, radiotherapy, chemotherapy, targeted therapy or other tumor-related interventions; 6. sign informed consent. exclusion criteria: 1. patients with diagnosed lung cancer and extrapulmonary malignant tumor; 2. pulmonary sarcoidosis, pulmonary vasculitis, pulmonary tuberculosis; 3. patients with poor compliance are expected to be unable to complete follow-up according to the study protocol; 4. major trauma requiring blood transfusion occurred within one week before enrollment; 5. pregnant and lactation patients.

Keywords: ctdna methylation ai analysis of ldct images
different ld of ticagrelor for antiplatelet effect in patients with non-st-segment elevation acs undergoing pci

Conditions: Non ST Segment Elevation Acute Coronary Syndrome

Summary: it is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(ipa) without increasing the bleeding events.

after providing written informed consent, all patients will be randomized to receive ticagrelor 360mg or 180mg loading dose(ld),then 90mg bid maintenance dose starting 12 hours after ld.pci will performed in 2h-72h after they are given the loading dose.all patients should receive acetylsalicylic acid (asa) 75 to 100 mg daily unless intolerant.ipa at 0, 0.5, 1, 2, 8, 24h after the loading dose of ticagrelor will be measured. ck-mb, troponin i, myoglobin, crp will be detected at 0h, before pci, 8h after pci, 24h after pci. ecg will be conducted at 0h and within 24h after pci. patients returned 28 days for follow-up visits after the loading dose of ticagrelor, documented any adverse events.

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures. * male or non-pregnant female; aged from 18 to 80 years old. * patients with non-st-segment elevation acute coronary syndromes who were scheduled to undergoing pci. exclusion criteria: * any contraindication against the use of ticagrelor. * on treatment with a p2y12 receptor antagonist in past 30 days. * known allergies to aspirin or ticagrelor. * on treatment with oral anticoagulant (vitamin k antagonists, dabigatran, rivaroxaban). * known blood dyscrasia or bleeding diathesis. * st-segment elevation acute myocardial infarction. * non-st segment elevation acute coronary syndrome with high-risk features warranting emergency coronary angiography. * left ventricular ejection fraction ≤30%; renal failure with creatinine 3 mg/dl; history of liver disease; an increased risk of bradycardia, and concomitant therapy with drugs interfering with cyp3a4 metabolism.

Keywords: ticagrelor loading dose non-st-segment elevation acute coronary syndromes percutaneous coronary intervention the antiplatelet effects bleeding events major adverse cardiac events
a dose-finding trial with lu-ag09222 in adults with migraine who have not been helped by prior preventive treatments

Conditions: Migraine

Summary: the purpose of this trial is to determine which doses of lu ag09222 are recommended to help prevent migraines. people who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.


Eligibility criteria:
key inclusion criteria: * the participant has a diagnosis of migraine as defined by international classification of headache disorders third edition (ichd-3) guidelines confirmed at the screening visit. * the participant has a history of migraine onset ≥ 12 months prior to the screening visit. * the participant has a migraine onset at ≤50 years of age. * the participant has ≥4 migraine days per month for each month within the past 3 months prior to the screening visit. * the participant has documented evidence of treatment failure in the past 10 years of at least 1 to 4 (maximum) different migraine preventive medications. key exclusion criteria: * the participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-pacap treatment). * the participant has confounding and clinically significant pain syndromes. * the participant has a diagnosis of acute or active temporomandibular disorder. * the participant has a history or diagnosis of confounding headaches. additional protocol-defined criteria apply.

Keywords: headache chronic migraine episodic migraine
study of acquired hemolytic anemia in adult hospitalized patients

Conditions: Hemolytic Anemia

Summary: the goal of the study is to identify the most common etiological factors and analyze the clinical presentations and laboratory findings in hospitalized patients with acquired hemolytic anemia associated with non-neoplastic diseases. and to evaluate short-term outcomes, including morbidity and mortality rates, and to determine correlations between specific etiological factors and patient outcomes in these cases.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and older. * patients diagnosed with acquired hemolytic anemia. * patients must be hospitalized in the internal medicine department at the time of diagnosis of acquired hemolytic anemia during the study period * patients (or their legal representatives) must provide informed exclusion criteria: * patients with underlying neoplastic diseases. * patients with hereditary hemolytic anemia. * patients or their representatives who do not consent to participate in the study.
a study of aleglitazar in monotherapy in patients with type 2 diabetes mellitus who are drug-naïve to anti-hyperglycemic therapy

Conditions: Diabetes Mellitus Type 2

Summary: this multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar monotherapy in patients with type 2 diabetes mellitus who are drug-naïve to anti-hyperglycemic therapy. patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks.


Eligibility criteria:
inclusion criteria: * adult patient, \>/= 18 years of age * diagnosis of type 2 diabetes mellitus within 12 months prior to screening * drug-naïve (defined as no anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months at any time in the past) * hba1c \>/= 7% and \</= 9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit * fasting plasma glucose \</= 13.3 mmol/l (\</= 240 mg/dl) at pre-randomization visit * agreement to maintain diet and exercise habits implemented during the run-in phase during the full course of the study exclusion criteria: * pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods * diagnosis or history of: 1. type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes 2. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months * any previous treatment with thiazolidinedione or with a dual peroxisome proliferator activated receptor (ppar) agonist * any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (\>= 1 month) statin therapy * prior intolerance to fibrate * triglycerides (fasting) \> 4.5 mmol/l (\> 400 mg/dl) at screening or within 4 weeks prior to screening * clinically apparent liver disease * anemia at or within 4 weeks prior to screening * inadequate renal function * symptomatic congestive heart failure new york heart association (nyha) class ii-iv at screening * myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit * known macular edema at screening or prior to screening visit * diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years * uncontrolled hypertension * history of active substance abuse (including alcohol) within the past 2 years
prospective case-control study of cardiovascular changes in pregnancy related hypertensive disorders

Conditions: Pre-Eclampsia

Summary: this is a research study to understand the changes in the heart and the cardiovascular system that may occur in women who develop high blood pressure during pregnancy.

upon enrollment in this study, participants will go through two scans along with some blood test and other assessments. the first scan is a sonogram of the heart called an echocardiogram, and another scan is done using the investigational artsens device that will be used to measure stiffness of the walls in the arterial blood vessel for indications of inflammation damage. artsens device is not approved for use in the united states. it is expected that we will enroll 50 people in this study. the entire study is expected to last 2 years. participation will be for approximately 9 months.

Eligibility criteria:
case inclusion criteria: 1. adult females age \> 18 years 2. must be able to read and understand english and consent for themselves 3. must have a singleton pregnancy and a diagnosis of preeclampsia or gestational hypertension 4. must be willing and able to come to west penn hospital for post-partum visits at 6-8 weeks and then at 6-7 months. case exclusion criteria: 1. prior history of hypertension 2. multiple pregnancies 3. other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as sle or severe lung disease. 4. subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. control inclusion criteria: 1. adult females age \> 18 years 2. must be able to read and understand english and consent for themselves 3. must have a singleton pregnancy and not have a prior or current diagnosis of hypertension 4. must be willing and able to come to west penn hospital for post-partum visits at 6-8 weeks. control exclusion criteria: 1. prior history and/or current diagnosis of hypertension 2. multiple pregnancies 3. other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as sle or severe lung disease. 4. subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
implementation of demonstration project for health systems: atrial fibrillation (inform-af) part 1

Conditions: Atrial Fibrillation

Summary: the goal of this study is to learn about the patient and provider perceptions, priorities, preferences, and willingness to use/prescribe anticoagulation as a stroke prevention therapy in patients with atrial fibrillation. qualitative interviews will be performed with atrial fibrillation patients and providers caring for atrial fibrillation patients. the investigators want to understand the factors that influence decision-making about anticoagulation medications, and to gain insight into patients' and providers' knowledge of the risk of stroke and bleeding associated with oral anticoagulation. this feedback will help provide better education to providers caring for patients with atrial fibrillation and better care to patients with atrial fibrillation by developing tools to optimize the appropriate use of oral anticoagulation for patients with atrial fibrillation.


Eligibility criteria:
patient inclusion criteria: 1. adult patient age 18 or older; 2. english speaking; 3. diagnosed atrial fibrillation; 4. at least 1 risk factor for congestive heart failure, hypertension, age, diabetes, stroke (chads2) or 2 risk factors for chads2 with vascular disease, age, and sex (chads2-vasc) ; 5. no documented cognitive impairment per the medical record; 6. not being prescribed an oral anticoagulant provider inclusion criteria: 1. physician at one of the study sites treating patients diagnosed with atrial fibrillation exclusion criteria: * none

Keywords: atrial fibrillation anticoagulation
role of kinesiotape over dorsi flexors muscles on balance in children with spastic diplegia

Conditions: Cerebral Palsy

Summary: to detect the effect of kinesio -tape on balance in children with spastic diplegia.

the use of kinesio taping might influence the cutaneous receptors of the sensory motor system, resulting in the improvement of voluntary control and coordination in a physiotherapy program for children with cp. (yasukawa et al., 2006). the study will be conducted to investigate the effect of kinesiotape applied on dorsi fexors muscles on improving balance in spastic diplegic children .

Eligibility criteria:
inclusion criteria: * • thirty children with spastic diplegia of both genders participated in this study. * theywere selected from the out-patient clinic, faculty of physical therapy, cairo university. * children height not less than 1 meter to be able to see the screen of the biodex balance system. * their agehad ranged from 4 to 8 years. * all patients have mild spasticity according to modified aschwar scale grade 1 \&1+ (alhusaini, 2010) presented in (appendix i). * all patients wereable to stand alone gmfm presented in (appendix ii). * they could understand and follow instructions. * all children used ankle foot orthosis. exclusion criteria: * • children with visual or auditory problems. * children with positive sensitivity to kinesiotape. * children with irrivisable muscle contracture at the calf muscles.
interest of gentamicin-induced readthrough in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: suppression of stop mutations in the cftr gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the cftr-mediated chloride transport in nasal and sweat gland epithelium.

background: this study was conducted to determine whether intravenous gentamicin can suppress stop codons in cystic fibrosis (cf) patients and, if so, whether it has any clinical benefits. methods: we first used a dual gene reporter system to determine the gentamicin-induced readthrough level of the most frequent cftr stop mutations in the french population. we next investigated readthrough efficiency in response to 10 mg/kg once daily intravenous gentamicin perfusions in patients with stop mutations and in a control group of patients without stop mutations. respiratory function, sweat chloride concentration, nasal potential difference (npd) and cftr expression in nasal epithelial cells were measured at baseline and after 15 days of treatment. results: after in vitro gentamicin incubation, the readthrough efficiency for the y122x mutation was at least five times higher than that for g542x, r1162x, and w1282x. in six of the nine patients with the y122x mutation, cftr immunodetection showed protein expression at the membrane of the nasal ciliated cells and the cftr-dependent chloride secretion in their npd measurements increased significantly. respiratory status also improved in these patients, irrespective of the gentamicin sensitivity of the germs present in the sputum. mean sweat chloride concentration decreased significantly and normalized in two patients. these measurements did not change in the y122x patients with no protein expression, in patients with the other stop mutations investigated in vitro (n=4) and those without stop mutations (n=5). conclusion: suppression of stop mutations in the cftr gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the cftr-mediated chloride transport in nasal and sweat gland epithelium.

Eligibility criteria:
inclusion criteria: * cystic fibrosis with cftr codon stop mutations exclusion criteria: * rhinitis * nasal polyposis * passive or active smoking * modification of basal treatments within the previous month * treatments with aminoglycosides within three previous months

Keywords: cystic fibrosis transmembrane conductance regulator premature termination codon gentamicin-induced readthrough
efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib.

Conditions: Gastrointestinal Stromal Tumors

Summary: this study will evaluate the preliminary efficacy of nilotinib in pretreated patients (imatinib, sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of gist that is unresectable and/or metastatic and therefore not amenable to surgery or combined modality with curative intent. * radiologically confirmed disease progression during imatinib therapy at a dose of at least 400 mg daily and/or radiologically confirmed disease progression during sunitinib therapy or documented intolerance to imatinib and/or sunitinib. (patients with prior additional investigational treatment of gist prior to study entry can be included.) * at least one measurable site of disease on ct/mri as defined by recist criteria. exclusion criteria: * prior treatment with nilotinib. * treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin c) prior to visit 1. * prior or concomitant malignancies requiring active treatment other than gist with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ. * impaired cardiac function at visit 1 * patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (gi) function, or gi disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes. other protocol-defined inclusion/exclusion criteria may apply

Keywords: gist imatinib sunitinib gastrointestinal stromal tumors